3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Rhabdomyosarcoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Temozolomide
30
Radiotherapy
23
Filgrastim
12
Carmustine
12
Irinotecan
11
Carboplatin
11
Chemotherapy, Adjuvant
9
O(6)-benzylguanine
8
Etoposide
7
Surgical Procedures, Operative
6
Magnetic Resonance Spectroscopy
6
Vincristine
5
Peripheral Blood Stem Cell Transplantation
5
Granulocyte Colony-Stimulating Factor
5
Cyclophosphamide
5
sargramostim
4
motexafin gadolinium
4
Topotecan
4
Thiotepa
4
Paclitaxel
4
Melphalan
4
Gene Expression Profiling
4
Gemcitabine
4
Drug Therapy
4
Busulfan
4
temsirolimus
3
etoposide phosphate
3
Specimen Handling
3
Mass Spectrometry
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Central Nervous System Neoplasms
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled